Emerging treatments
Roxadustat
Roxadustat (an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor) stimulates erythropoiesis and regulates iron metabolism. In a phase 3 trial of patients with chronic kidney disease not undergoing dialysis, treatment with roxadustat resulted in a higher mean hemoglobin level compared with placebo.[182] Roxadustat demonstrated continued efficacy in the open-label phase of the trial.[182] In a study of patients with anemia undergoing dialysis, roxadustat demonstrated noninferiority to epoetin alfa.[183]
Use of this content is subject to our disclaimer